Letter to the Editor: ETV6-NTRK2 Fusion Identified in a Patient with Medullary Thyroid Carcinoma

Ciampi R , Romei C , Ramone T , et al. Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing. iScience, 2019; 20:324–336; doi: 10.1016/j.isci.2019.09.030

Pekova B , Sykorova V , Mastnikova K , et al. NTRK fusion genes in thyroid carcinomas: clinicopathological characteristics and their impacts on prognosis. Cancers (Basel), 2021; 13(8):1932; doi: 10.3390/cancers13081932

Park JC , Ashok A , Liu C , et al. Real-world experience of NTRK fusion-positive thyroid cancer. JCO Precis Oncol, 2022; 6:e2100442; doi: 10.1200/PO.21.00442

Manea CA , Badiu DC , Ploscaru IC , et al. A review of NTRK fusions in cancer. Ann Med Surg (Lond), 2022; 79:103893; doi: 10.1016/j.amsu.2022.103893

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Thyroid Carcinoma V.3.2022. © National Comprehensive Cancer Network, Inc., 2023. All rights reserved. Available from: NCCN.org (Last accessed: accessed March 6, 2023 ).

Waguespack SG , Drilon A , Lin JJ , et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol, 2022; 186(6):631–643; doi: 10.1530/EJE-21-1259

Doebele RC , Drilon A , Paz-Ares L , et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol, 2020; 21(2):271–282; doi: 10.1016/S1470-2045(19)30691-6